• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Amgen

Amgen completes $1.9B acquisition of Five Prime Therapeutics

April 16, 2021 By Sean Whooley

Amgen Five Prime Therapeutics

Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021. As of the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology, Pharmaceuticals Tagged With: Amgen, Five Prime Therapeutics

Amgen to acquire Five Prime Therapeutics for $1.9B

March 4, 2021 By Sean Whooley

Amgen Five Prime Therapeutics

Amgen (NSDQ:AMGN) announced today that it is set to acquire Five Prime Therapeutics (NSDQ:FPRX) for approximately $1.9 billion. Thousand Oaks, Calif.-based Amgen will acquire South San Francisco-based Five Prime for $38 per share in cash, reaching the equity value of approximately $1.9 billion, according to a news release. Amgen is set to add Five Prime’s pipeline […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Oncology, Pharmaceuticals Tagged With: Amgen, Five Prime Therapeutics

Pharma stocks fall as Rep. Cummings launches drug pricing investigation

January 14, 2019 By Sarah Faulkner

Pills

Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the investigation saw their stock prices fall, including Amgen (NSDQ:AMGN), AbbVie (NYSE:ABBV), AstraZeneca (NYSE:AZN), Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). A hearing is reportedly set for Jan. 29 and will […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Amgen, AstraZeneca plc, Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

Amgen touts lowered prices for Repatha delivery devices

January 8, 2019 By Sarah Faulkner

Amgen updated logo

Amgen (NSDQ:AMGN) said today that it lowered the list prices of the drug-delivery devices for its cholesterol drug, Repatha, to $5,850 per year. The Thousand Oaks, Calif.-based company touted the 60% discount as a way to boost patient affordability and accessibility. The Repatha SureClick autoinjector, which Amgen said is the most commonly used delivery device for […]

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Amgen

Teva wins FDA nod for migraine prevention drug

September 17, 2018 By Sarah Faulkner

Teva Pharmaceutical's Ajovy migraine drug

Teva (NYSE:TEVA) last week won FDA approval for its humanized monoclonal antibody, Ajovy, designed to prevent migraines. The treatment, which blocks the receptor for a protein that is linked to migraine pain, is available in quarterly and monthly-injection options. Amgen‘s (NSDQ:AMGN) competitive once-monthly product won FDA approval earlier this year. Teva studied Ajovy in two Phase […]

Filed Under: Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Teva Pharmaceuticals

EMA committee recommends approval for migraine prevention drug

June 1, 2018 By Sarah Faulkner

Novartis

Novartis (NYSE:NVS) said today that a committee for the European Medicines Agency has recommended that the regulatory agency approve Aimovig, a self-administered drug designed to prevent migraines in adults who have at least four migraine days each month. The drug is the first of a new class of medicines, called CGRP inhibitors. It’s a monoclonal antibody […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Novartis

With groundbreaking approval, Amgen launches new class of medicine for migraine patients

May 18, 2018 By Sarah Faulkner

Amgen

Amgen (NSDQ:AMGN) won FDA approval this week for its once-monthly Aimovig injection designed to prevent the onset of migraines in adults. The drug is the first of its kind – a molecule that blocks the receptor for a protein that is linked to migraine pain, the calcitronin gene-related peptide. Other major pharmaceutical companies like Eli Lilly (NYSE:LLY) […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Eli Lilly & Co., Teva Pharmaceuticals

EMA committee backs Amgen’s on-body injector for Neulasta

February 27, 2018 By Sarah Faulkner

Amgen

Amgen (NSDQ:AMGN) said today that a committee for the European Medicines Agency has recommended that the regulatory body approve a label variation for its Neulasta product to include the Onpro on-body injector delivery device. Neulasta’s Onpro kit includes a pre-filled syringe paired with a single-use on-body injector. The lightweight device is given to the patient on the […]

Filed Under: Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen

Amgen swings to a loss in Q4 after $6B hit from tax reform

February 2, 2018 By Sarah Faulkner

Amgen

Shares in Amgen (NSDQ:AMGN) rose slightly today after the biotech missed expectations on Wall Street with its fourth-quarter earnings, but topped EPS estimates for the year ahead. The Thousand Oaks, Calif.-based company swung to a net loss in Q4 thanks to a $6 billion tax charge, posting -$4.26 billion on sales of $5.8 billion in the […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Amgen

Amgen launches Enbrel Mini single-dose cartridges with reusable auto-injector

November 17, 2017 By Sarah Faulkner

Amgen auto-injector

Amgen (NSDQ:AMGN) announced today the U.S. launch of its Enbrel Mini single-dose prefilled cartridges, which are delivered using a reusable AutoTouch auto-injector. The drug-device combination was designed with a needle that stays hidden during injection and a sensor to detect placement on the skin. Amgen’s latest product uses a new drug formulation of Enbrel, an injectable […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Amgen

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS